Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleRandomised controlled study of cannabis-based medicine (Sativex®) in patients suffering from multiple sclerosis associated detrusor overactivity
Author(s)de Ridder D, Constantinescu CS,Fowler C, Kavia R, Sarantis N.
Journal, Volume, Issue22nd Congress of the ECTRIMS, 27-30 September 2006, Madrid, Spain.
Major outcome(s)A significant reduction in the number of voids per day and during the night.
IndicationMultiple sclerosisAbstract
MedicationCannabis

Bladder problems are a common feature of Multiple Sclerosis (MS), with up to 80% of MS subjects experiencing voiding dysfunction..
Methods: A 10 week double blind, randomized, placebo controlled parallel group trial was conducted. After a 2 week baseline period, 135 subjects with MS and detrusor overactivity were randomized to receive either Sativex (a standardised whole plant cannabis medicine), or placebo. The primary end point was a reduction in the daily number of episodes of urgency incontinence. Other end points included incidence of nocturia and urgency, overall bladder condition (measured on an 11-point numerical rating scale), daytime frequency, quality of life, patientís global impression of change (PGIC) and volume voided.
Results: For the primary endpoint, the decrease from baseline in incontinence episode frequency per day was in favour of the Sativex treated group but was not statistically significant (-1.08, p=0.57). Of the secondary/tertiary end points, 10 of the 11 were in favour of Sativex. In 4 out of 7 secondary end points there was statistical significance in favour of Sativex. These were reduction in nocturia episodes (-0.28, p=0.010); highly statistically significant improvement in patientís opinion of bladder symptom severity (-1.16 points, p=0.001); reduction in the number of voids per day (-0.85, p=0.007) and PGIC where 83.6% of subjects receiving Sativex compared with 58.2% receiving placebo considered the status of their bladder condition had improved (odds ratio 2.56, p=0.005). The decrease in number of urgency episodes in Sativex treated subjects just failed to reach statistical significance (-0.76, p=0.071). Of the tertiary end points, the number of daytime voids was statistically significantly in favour of Sativex (-0.57, p=0.044). There was a trend in favour of improvement in Quality of Life but which did not reach statistical significance.
Conclusions: Sativex treatment had a positive impact on the symptoms of overactive bladder in multiple sclerosis patients. It provides qualitative and quantitative symptomatic improvement and a normalisation of the symptoms of urinary frequency for many subjects with MS and further research is warranted.

Route(s)Sublingual
Dose(s)
Duration (days)70
Participants135 patients with multiple sclerosis and bladder problems
DesignControlled study
Type of publicationMeeting abstract
Address of author(s)
Full text

[Back to Overview]  [IACM Homepage]


up